Can you take tesamorelin and retatrutide together? This is an increasingly asked question as interest in advanced metabolic and body composition treatments grows. Tesamorelin is a synthetic growth hormone-releasing hormone analogue used in some countries for HIV-associated lipodystrophy, whilst retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) currently in Phase 3 trials. Neither holds a UK marketing authorisation from the MHRA. This article examines how each medicine works, what is currently known about their combined use, the potential risks involved, and why specialist medical guidance is essential before considering either agent.

How Tesamorelin and Retatrutide Work in the Body

Tesamorelin stimulates pituitary GH release to reduce visceral fat via the GH/IGF-1 axis, whilst retatrutide is a tri-agonist targeting GLP-1, GIP, and glucagon receptors to suppress appetite and improve metabolism; neither holds UK marketing authorisation.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It works by binding to GHRH receptors in the pituitary gland, stimulating the pulsatile release of endogenous growth hormone (GH). Elevated GH in turn raises insulin-like growth factor 1 (IGF-1) levels and promotes lipolysis — particularly the breakdown of visceral adipose tissue. It is important to note that tesamorelin does not hold a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It is licensed in some countries — including the United States and Canada — for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, but any use in the UK would be on an unlicensed basis, typically via a named patient or specials route under specialist supervision.

Retatrutide is an investigational triple receptor agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tri-agonist mechanism produces a combination of effects: enhanced insulin secretion, reduced appetite and caloric intake, increased energy expenditure, and improved lipid metabolism. Published Phase 2 trial data (NEJM, 2023) demonstrated substantial reductions in body weight — in some participants exceeding 20% over approximately 48 weeks — making retatrutide one of the most potent agents currently in development for obesity and metabolic disease. Phase 3 trials are ongoing; retatrutide has not yet received marketing authorisation from the MHRA or EMA, and its use in the UK remains restricted to clinical trial settings.

Although both agents influence body composition and fat metabolism, they do so through entirely distinct biological pathways. Tesamorelin acts via the GH axis: it is GH itself that primarily reduces insulin sensitivity, whilst IGF-1 — also elevated by tesamorelin — has insulin-like properties that may partially counterbalance this effect. Retatrutide operates through incretin and glucagon signalling. Understanding these separate mechanisms is essential when considering whether the two could be used together, as their pharmacological profiles do not directly overlap, but their downstream metabolic effects may interact in clinically meaningful ways.

Potential Interactions Between These Two Medicines

No formal interaction studies exist, but pharmacodynamic interactions are a key concern — tesamorelin raises blood glucose whilst retatrutide lowers it, making the combined glycaemic effect unpredictable and requiring close clinical monitoring.

Because tesamorelin and retatrutide act on different receptor systems, no formal pharmacokinetic interaction studies have been conducted; based on their mechanisms, a clinically significant interaction affecting absorption, distribution, metabolism, or excretion of either agent seems unlikely. However, pharmacodynamic interactions — where the combined effects of two drugs influence the same physiological outcomes — are a more relevant concern.

Both agents affect glucose homeostasis, albeit differently. Tesamorelin raises GH levels, which reduces insulin sensitivity and can elevate blood glucose. Retatrutide, conversely, enhances insulin secretion and improves glycaemic control through its GLP-1 and GIP receptor activity. In theory, these opposing effects on glucose metabolism could partially offset one another, but the net result in any individual patient is difficult to predict without close clinical monitoring. There is a plausible risk that the glucose-raising effects of tesamorelin could blunt some of the glycaemic benefits of retatrutide.

An additional and important caution applies if either agent is used alongside insulin or a sulfonylurea: retatrutide's glucose-lowering activity may increase the risk of hypoglycaemia in this context, and dose review of any existing antidiabetic medicines would be essential before combining treatments.

Both medicines also influence lipid metabolism and visceral fat. Combining agents with overlapping metabolic targets raises questions about additive versus synergistic effects, and whether the benefit-to-risk ratio improves or worsens with dual use. Gastrointestinal side effects — particularly nausea, which is common with retatrutide — could also be compounded. Patients should be aware that severe or persistent abdominal pain may be a sign of pancreatitis or a gallbladder complication, consistent with the GLP-1 receptor agonist class, and warrants urgent medical assessment. No formal drug interaction studies between tesamorelin and retatrutide have been published, and any assumptions about their combined safety profile remain speculative.

What the Current Evidence Says About Combined Use

There is no published clinical trial, regulatory guidance, or peer-reviewed evidence supporting the combined use of tesamorelin and retatrutide; both are unlicensed in the UK, making combined use an area of significant clinical and regulatory uncertainty.

At present, there is no published clinical trial, regulatory guidance, or peer-reviewed evidence specifically examining the combined use of tesamorelin and retatrutide. Retatrutide remains an investigational medicine with no MHRA or EMA marketing authorisation as of early 2025; its use outside of clinical trials in the UK is therefore unlicensed. Combining it with another unlicensed agent such as tesamorelin would add a further layer of clinical and regulatory uncertainty.

Tesamorelin similarly has no UK marketing authorisation. Any prescribing in the UK occurs via a named patient or specials route, under the supervision of a specialist clinician and in accordance with Specialist Pharmacy Service (SPS) and MHRA guidance on unlicensed medicines. This regulatory context is important: both medicines sit outside standard NHS prescribing pathways for most patients, and robust safety data in real-world UK populations is limited.

Whilst the concept of combining agents that target different metabolic pathways is well established in conditions such as type 2 diabetes, there is no specific peer-reviewed evidence supporting the combination of GH-axis modulators with incretin-based therapies in obesity or metabolic-associated steatotic liver disease (MASLD). Any suggestion that such a combination is supported by the existing literature should be treated with caution. This remains an area of active research rather than established clinical practice, and until adequately powered, randomised controlled trials assess the safety and efficacy of this specific combination, clinicians and patients should approach any claims about its benefits with appropriate scepticism.

Risks and Safety Considerations to Discuss With Your Doctor

Combined use may compound individual risks including unpredictable glycaemic fluctuations, fluid retention, nausea, gallbladder complications, and pancreatitis; regular monitoring of glucose, HbA1c, IGF-1, and liver function is essential.

Both tesamorelin and retatrutide carry individual risk profiles that must be carefully considered before any combined use is contemplated. For tesamorelin, known adverse effects (based on US and Canadian prescribing information, as no UK Summary of Product Characteristics exists) include:

• Fluid retention (oedema, joint pain, carpal tunnel syndrome)

• Elevated blood glucose and reduced insulin sensitivity due to GH elevation

• Injection site reactions

• Raised IGF-1 levels — active malignancy is a key contraindication; individuals with a personal history of cancer should discuss this explicitly with their specialist before use

Retatrutide's side effect profile, based on published Phase 2 trial data (with Phase 3 trials ongoing), includes:

• Nausea, vomiting, and diarrhoea — particularly during dose escalation

• Reduced appetite, which may lead to nutritional deficiencies if not monitored

• Increased heart rate

• Gallbladder-related complications, including cholelithiasis, consistent with the GLP-1 receptor agonist class

When used together, these risks may compound. The opposing effects on blood glucose could create unpredictable glycaemic fluctuations, particularly in individuals with pre-existing diabetes or impaired glucose tolerance. If either agent is used alongside insulin or a sulfonylurea, the risk of hypoglycaemia is increased and medication doses should be reviewed by a clinician.

Neither tesamorelin nor retatrutide has an established safety profile in pregnancy or breastfeeding. As investigational or unlicensed agents, their use during pregnancy or whilst breastfeeding is not recommended. Women of childbearing potential should discuss appropriate contraception with their clinician before starting either medicine.

Patients should seek urgent medical attention if they experience:

• Severe or persistent abdominal pain (possible pancreatitis or gallbladder complication)

• Signs of dehydration (dizziness, reduced urine output) due to vomiting or diarrhoea

• Symptoms of hypoglycaemia (shakiness, sweating, confusion) or hyperglycaemia (excessive thirst, frequent urination)

• Severe headache or visual disturbance (possible raised intracranial pressure)

• Signs of an allergic reaction (rash, swelling, difficulty breathing)

Regular monitoring should include fasting glucose, HbA1c, IGF-1, lipid panels, liver function, and renal function. If severe abdominal pain occurs, measurement of serum amylase and lipase should be considered.

Patients and healthcare professionals are encouraged to report any suspected adverse reactions to the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk). This is particularly important for unlicensed and investigational medicines, where post-market safety data are limited.

When Combined Metabolic Treatments May Be Considered

Combining these agents falls well outside current NICE guidance and NHS practice; any theoretical consideration would require a formal clinical trial setting, multidisciplinary oversight, documented informed consent, and a clear monitoring plan.

The concept of combining agents that target different metabolic pathways is well established in medicine. In type 2 diabetes management, for example, NICE guideline NG28 supports the use of multiple agents with complementary mechanisms when monotherapy is insufficient. However, this principle does not extend to an endorsement of combining tesamorelin with retatrutide — there is no NICE guidance, NHS pathway, or published evidence base supporting this specific combination.

In highly specialised settings, a clinician might theoretically consider combining a GH-axis modulator with an incretin-based therapy for a patient with a specific, well-characterised metabolic phenotype — for instance, significant visceral adiposity in the context of HIV-associated lipodystrophy — who has not responded adequately to standard treatments. However, this would represent an off-label, experimental approach that falls well outside current NICE guidance or standard NHS practice, and should only ever be considered within a formal clinical trial or with robust multidisciplinary oversight, documented informed consent, and a clear monitoring plan.

Retatrutide's availability in the UK remains restricted to clinical trial settings. Patients interested in accessing retatrutide should enquire about eligibility for ongoing trials through their specialist or via the NIHR's Be Part of Research website (bepartofresearch.nihr.ac.uk). Combining investigational agents with other unlicensed medicines outside of a formal trial protocol raises significant ethical and safety concerns and should not be undertaken without appropriate clinical governance.

Seeking Guidance From a UK Specialist or Prescriber

Patients should consult a UK endocrinologist, metabolic physician, or obesity medicine specialist before considering either agent; sourcing these medicines from unregulated online pharmacies is strongly discouraged by the MHRA.

If you are considering whether tesamorelin and retatrutide could be used together, the most important first step is to speak with a qualified UK specialist — typically an endocrinologist, metabolic physician, or obesity medicine specialist. These clinicians have the expertise to assess your individual metabolic profile, review your full medication history, and advise on whether any combination approach is appropriate, safe, or accessible within the current regulatory framework.

Your GP can provide an initial referral to an NHS endocrinology or metabolic service if there is a clinical indication. For patients with HIV-associated lipodystrophy, specialist HIV clinics — guided by BHIVA recommendations on metabolic complications — may have more direct experience with tesamorelin. For those seeking access to retatrutide, your specialist can advise on whether any active clinical trials are recruiting in your region; the NIHR's Be Part of Research website is a useful starting point.

It is strongly advisable not to source either of these medicines from unregulated online pharmacies or private compounding services without verified medical supervision. The MHRA has issued repeated warnings about the risks of purchasing unlicensed injectable medicines online, including risks of contamination, incorrect dosing, and absence of clinical oversight. Guidance on buying medicines safely online is available at gov.uk/mhra. For information on the governance of unlicensed medicines in the UK, the Specialist Pharmacy Service (SPS) provides authoritative guidance for both clinicians and patients.

Any treatment plan involving these agents should include:

• Regular blood tests (glucose, HbA1c, IGF-1, lipids, liver function, renal function)

• Documented informed consent regarding off-label or investigational use

• Dietitian input to monitor nutritional status, particularly during periods of rapid weight loss or reduced appetite

• Reconciliation of all concomitant medicines, including over-the-counter products and supplements, to minimise interaction risks

• Clear escalation pathways if side effects arise, including urgent review for severe abdominal pain, dehydration, or hypoglycaemia

• Ongoing review by a named responsible clinician

• Reporting of any suspected adverse effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)

Your health and safety are best protected by working transparently within the NHS or a regulated private medical setting, with full disclosure of all medicines — prescribed or otherwise — that you are taking.

Frequently Asked Questions